Role for Low-Contrast Acuity as Part of a New MS Disability Composite Measure

Update Item Information
Identifier 20110208_nanos_posters_118
Title Role for Low-Contrast Acuity as Part of a New MS Disability Composite Measure
Creator Laura Balcer; Steven Galetta; Richard Rudick; Chris Polman; Christophe Hotermans; Annie Zhang; Robert Hyde
Affiliation (LB) (SG) University of Pennsylvania, Philadelphia, PA; (RR) Cleveland Clinic Foundation, Cleveland, OH; (CP)Vrije Universiteit Medical Centre, Amsterdam, Netherlands; (CH) (AZ) (RH) Biogen Idec Inc., Weston, MA
Subject Low-Contrast Acuity; Vision; Multiple Sclerosis; Disability; Natalizumab
Description In the AFFIRM trial of natalizumab vs. placebo for relapsing multiple sclerosis (MS), there was a reduction in sustained loss of low-contrast acuity (LCA) for patients on natalizumab. LCA captures information on visual function not entirely captured by the Expanded Disability Status Scale (EDSS) or the MS Functional Composite (MSFC), making these measures complementary for assessing disability.
Date 2011-02-08
Language eng
Format application/pdf
Type Text
Source 2011 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of NANOS 2011: Poster Presentations
Collection Neuro-ophthalmology Virtual Education Library: NOVEL http://NOVEL.utah.edu
Publisher Spencer S. Eccles Health Sciences Library, University of Utah
Holding Institution North American Neuro-Ophthalmology Association. NANOS Executive Office 5841 Cedar Lake Road, Suite 204, Minneapolis, MN 55416
Rights Management Copyright 2011. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright
ARK ark:/87278/s6t470km
Context URL The NANOS Annual Meeting Neuro-Ophthalmology Collection: https://novel.utah.edu/collection/NAM/toc/
Setname ehsl_novel_nam
ID 181741
Reference URL https://collections.lib.utah.edu/ark:/87278/s6t470km